SALES

Dyneval & CPACT join forces to solve the industry’s biggest particle sizing bottleneck

The world of advanced therapeutics, lipid nanoparticles (LNPs), and complex formulations is moving faster than ever. Yet scientists and process engineers still face a frustrating, decades-old bottleneck: the inability to accurately measure particle-size distributions in highly concentrated, polydisperse samples without altering them.

To solve this problem and drive the next generation of Process Analytical Technology (PAT), Dyneval is proud to announce its official membership with CPACT (Centre for Process Analytics and Control Technology).

A Strategic Alliance for Advanced PAT

Dyneval’s induction into CPACT represents a powerful synergy between a cutting-edge Scottish technology pioneer and Europe’s premier community for process analysis and control. Founded by physicists from the University of Edinburgh, Dyneval specialises in turning complex microscale motion into actionable data. By joining forces with CPACT, Dyneval aims to directly address the manufacturing and quality-control bottlenecks that are currently stalling high-stakes industries.

"Dyneval is thrilled to join CPACT to work with world leaders in PAT technology. Our team looks forward to addressing unmet needs of the industry with the Lumero range, where concentration no longer hinders precise measurement of particle size distributions and contamination."

Dr. Tiffany Wood, CEO & Co-founder of Dyneval

The Innovation: What Makes Lumero Different?

Traditional particle size analysis often forces scientists to compromise: they must dilute almost every sample to make it readable, or risk unreliable and misleading results. However, dilution is far from harmless. It can fundamentally alter the structure, stability, and aggregation behaviour of sensitive, complex formulations.

The Lumero® S1 particle size analyser completely bypasses this limitation. It is engineered to size complex suspensions ranging from tens of nanometers to several microns under their native, unmodified conditions.

"With Lumero, we’ve built a ground-breaking particle size analyser that delivers complete particle size distributions across an exceptionally wide concentration range. By drastically reducing or even removing the need for dilution, and simultaneously capturing aggregates that cause product failure alongside the target particles (e.g. Lipid Nanoparticles), Lumero makes it much easier to uncover hidden issues and accelerate R&D, de-risk processing, and ensure formulation stability."

Dr Joe Bradley, Lumero Product Manager

Key Technical Capabilities at a Glance

  • Minimised Dilution Requirements: Thanks to an exceptionally wide concentration range, the Lumero S1 significantly reduces the need for sample dilution, allowing many complex or opaque industrial suspensions to be measured closer to or exactly in their native state.
  • User-Independent Repeatability: Streamlined, automated software ensures that anyone on the team can achieve precise, highly reproducible data with minimal training.
  • Contamination & Aggregation Detection: High sensitivity across the nano-micro scale allows early tracking of unwanted formulations, structural degradation, or contaminants.
  • The Path to Real-Time Monitoring: While currently optimised as an intuitive at-line or offline benchtop device, Dyneval is working with partners in CPACT as part of a large collaborative grant to actively advance the development of an online device designed for direct integration into active manufacturing pipelines.

Collaborative Opportunities for CPACT Members

Dyneval is actively inviting fellow CPACT members and industry partners to investigate a wide array of challenging materials. Backed by extensive contract research expertise, the Dyneval team is looking to co-develop solutions and run sample testing focused on three core areas:

  • Thorough Physical Characterisation: Utilising key expertise and Dyneval’s unique technology to investigate sample properties and the impact of sample dilution.
  • Formulation Stability: Tracking how complex mixtures age and interact over time without disrupting the native environment.
  • Broad Material Testing: Inviting partners to explore how Lumero technology handles highly complex, dense, or traditionally “un-measurable” industrial suspensions.

Partner with us

Struggling with sample dilution, early-stage aggregation, or real-time quality control? The Dyneval team wants to hear from you. Talk to us or connect via the CPACT network to solve your toughest formulation challenges.
GET IN TOUCH!

Frequently Asked Questions: Particle Sizing & PAT

Learn how next-generation particle sizing and PAT approaches enable accurate analysis of concentrated, complex suspensions using Lumero technology.

How does the Lumero S1 analyse particle size distributions in concentrated suspensions?

Lumero uses Dyneval’s propietary VISTA (Video Intensity Spatio-Temporat Analysis) algorithm to extract particle dynamics from intensity fluctuations. The nature of this algorithm removes the issues of multiple scattering and resolution limits, so lets Lumero measure complex suspensions more closely to their native state. By significantly expanding the operational concentration window, it minimises or eliminates the heavy sample dilution required by traditional light-scattering techniques.

Diluting samples, especially complex formulations, can fundamentally alter their physical structures, change the thermodynamic environment, and destabilise the mixture. In lipid or surfactant containing formulations, self assembled structures can be completely lost, and in sucrose-containing samples changes in osmotic pressure can lead to particle growth. Dilution often disrupts or breaks apart early-stage aggregates, masking critical instabilities and leading to inaccurate quality control data.

Process Analytical Technology (PAT) for particle sizing is crucial in high-stakes fields where formulation integrity is paramount. Key applications include optimising lipid nanoparticle (LNP) delivery systems, ensuring batch consistency in advanced therapeutics and animal health, tracking nucleation kinetics, and monitoring long-term formulation stability.

Latest